KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Interest & Investment Income (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Interest & Investment Income data on record, last reported at $24.7 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 14.46% year-over-year to $24.7 million; the TTM value through Dec 2025 reached $97.8 million, down 8.65%, while the annual FY2025 figure was $97.8 million, 8.65% down from the prior year.
  • Interest & Investment Income reached $24.7 million in Q4 2025 per IONS's latest filing, up from $23.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $28.9 million in Q4 2024 and bottomed at $872000.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $16.5 million, with a median of $22.2 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: plummeted 86.49% in 2021, then soared 834.62% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $1.8 million in 2021, then soared by 557.3% to $11.9 million in 2022, then soared by 116.14% to $25.7 million in 2023, then increased by 12.55% to $28.9 million in 2024, then fell by 14.46% to $24.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $24.7 million in Q4 2025, $23.7 million in Q3 2025, and $24.7 million in Q2 2025.